Prognostic Values of Long Noncoding RNA linc00152 in Various Carcinomas: An Updated Systematic Review and Meta-Analysis.

Abstract

Dysregulation of the long noncoding RNA linc00152 has been reported in various solid tumors. Here, we performed a synthetic analysis to clarify the clinical value of linc00152 as a prognostic indicator in malignant tumors. Article collection was conducted using several electronic databases, including PubMed, Web of Science, Medline, OVID, and Embase (up to February 13, 2018). The meta-analysis comprised nine original studies and 808 total patients. The application of a random-effects model revealed significant positive association between high expression level of linc00152 and lymph node metastasis (odds ratio [OR] = 2.93, 95% confidence interval [CI]: 1.88-4.57, p < .0001; I2 = 48.8, p = .119) and negative association with low-grade cancer (OR = 2.43, 95% CI: 1.51-3.92; I2 = 61.7, p = .033), while with tumor recurrence (hazard ratio [HR] = 3.32, 95% CI: 1.98-5.57, p < .0001; I2 = 0, p = .451) by fixed-effects model as the low heterogeneity. As demonstrated via the application of the fixed-effects model, Linc00152 overexpression is positively related to poor overall survival (pooled HR = 1.98, 95% CI: 1.70-2.31, p < .0001; I2 = 0%, p = .756) and poor disease-free survival (HR = 1.66, 95% CI: 1.20-2.29, p < .0001; I2 = 75.8%, p = .042) in human solid cancers. Statistically significant associations were additionally found with cancer type, sample size, and follow-up time. In conclusion, linc00152 is of potential value as a novel biomarker of lymph node metastasis and prognosis in human cancer. IMPLICATIONS FOR PRACTICE: linc00152 is of potential value as a novel biomarker of lymph node metastasis and prognosis in human cancer.